ORÍ

For Investors · Confidential

Orí is
inevitable.

This page exists to answer the questions a serious investor asks before the second meeting. Market. Science. Moat. Regulation. Defensibility. The thesis without the deck.

Financials, valuation, and round structure are not published here. Reach the founder directly for the full data room and business plan.

Three Independent Confirmations

Before Orí raised
a single dollar,
three forces converged.

I

Demand

MiroFish proprietary simulation

AI agents representing religious scholars, legal experts, clinical psychologists, AI ethicists, mental health professionals, government policy advisors, and technology journalists were interviewed about Orí before the product existed. A type of pre-launch market research 99% of pre-seed companies have never had access to. Findings: ethical architecture cited as primary trust driver above hardware, price, or brand. Category confirmed unoccupied. Government lobbying as mental-health infrastructure confirmed viable.

II

Science

MIT AlterEgo · the input layer is real

Arnav Kapur at MIT Media Lab demonstrated neuromuscular signals from jaw, throat, and facial muscles can be decoded with 92% word accuracy at over 100 wpm, without opening the mouth, without making a sound. AlterEgo spun out of MIT in early 2025, confirming commercial viability. Orí does not require this technology to function today. But Orí is the only presence system architected to receive subvocal signal as it matures, because Orí was built around the principle that silence is data equal to speech.

III

Market

OpenAI Sweetpea · 40-50M units year one

January 2026: OpenAI announced Sweetpea, a ChatGPT-powered behind-the-ear wearable designed by Jony Ive, manufactured by Foxconn, targeting 40-50M units in its first year, launching H2 2026. OpenAI acquired Jony Ive's hardware company io for $6.5B to build it. Sweetpea is the attention-economy version of what Orí is. Cloud-dependent. Always-on ChatGPT. Engagement-optimized. Same ear. Opposite philosophy. Sweetpea's announcement confirms three things: the category is commercially viable at massive scale, the form factor is correct, and the market is ready now.

A woman wearing Orí, listening

Same ear. Opposite soul.

Defensibility

Six structural moats.
Architectural, not feature-based.

01

Architectural impossibility for OpenAI

Sweetpea cannot become Orí. Its revenue model requires engagement optimization. Its cloud architecture requires data to leave the device. Its business model requires monetization of the relationship. Orí's local-first, refusal-capable, anti-engagement architecture makes all three structurally impossible, not difficult, impossible.

02

Trust is the product, not the wrapper

MiroFish demand simulation showed unanimously: across religious scholars, clinicians, AI ethicists, policy advisors and journalists, the ethical architecture was cited as the primary driver of trust above hardware, price, and brand. In an AI category increasingly defined by extraction, refusal becomes the most defensible position on the board.

03

Same form factor, opposite philosophy

OpenAI's Sweetpea (40-50M units year one, Foxconn-built, Jony-Ive designed) confirms the form factor and the addressable market. Orí is positioned as the conscientious-objector alternative for the most valuable users in the category, the ones who will not put cloud-dependent always-on ChatGPT in their ear.

04

Regulatory anchor at seed

FDA-cleared precedent for PPG-based AF detection (AliveCor 2014, Apple 2018). FDA Voice Biomarker AI in Mental Health guidance now exists. Nature Digital Medicine 2026 confirmed cross-language speech biomarkers for cognitive impairment. Most health-tech startups do not have a regulatory anchor at seed. Orí does.

05

62+ peer-reviewed citations

The Clinical Appendix maps every detection claim to current evidence tier, cleared, strong, or roadmap. This tiered transparency is not a weakness. For sophisticated health-tech investors, it is the strongest credibility signal at the stage. We never claim more than the literature supports.

06

Aging care: the strongest vertical

Jewelry, not a medical alert button. The first wearable elders will actually wear, because it does not announce frailty. Combined gait, voice, and physiology sensing per BMJ Open 2025. Reimbursement pathway. Family-payer dynamic. The fourth utility of later life.

The Questions Asked

The seven questions
that come up first.

01Why now?+

Three forces converged in the same 18-month window: OpenAI/Jony Ive validated the form factor at 40-50M units; MIT AlterEgo proved subvocal interface is commercially viable; FDA published Voice Biomarker AI guidance. The category, the science, and the regulator all confirmed in 2025-2026. Before this window, Orí could not have shipped credibly. After it, the category will be commoditized by attention-economy players.

02What stops a giant from copying this?+

Their business model. Anti-engagement architecture is not a feature OpenAI, Meta, or Google can ship, it terminates their unit economics. Apple is the only player who could try, and Apple's HealthKit, Siri, and App Store ecosystems are all built around developer engagement. Orí's moat is structural: a competitor would have to first dismantle their existing revenue engine.

03How is this not just another wellness wearable?+

Wellness wearables sell metrics. Orí is a presence engine, the metric layer is one tier of four. Tier II (refusal logic, dependency dampening, the Vow Engine) does not exist in any commercial product. Tier IV (longitudinal behavioral change, the fourth utility) becomes possible only when memory is sovereign. The hardware is the entry point. The architecture is the company.

04What is the worst case?+

MiroFish identified it: a data breach of emotional memory. This is a security engineering problem, not a market rejection problem. AES-256 encryption, local-first architecture, biometric-gated access, and zero-knowledge cloud are all already-solved primitives. The worst-case scenario is one we have already engineered against, by design, before any user is onboarded.

05What about regulation?+

We welcome it. Orí is consent-first by architecture. HIPAA, GDPR, the EU AI Act, and emerging US state laws all push the market in our direction. MiroFish confirmed government partnership as mental-health infrastructure is viable. We expect to be a beneficiary of regulation, not a casualty of it.

06Why a luxury price point?+

Two reasons. First, the materials and manufacturing, 18K recycled gold, Grade 5 titanium, NGK EnerCera battery, posterior auricular PPG, are not commodity. Second, luxury creates the social permission for the wearer to be seen with it. A medical device announces frailty. Jewelry announces taste. Aging care alone justifies the positioning.

07Where does Orí go after the ear?+

Nowhere. The ear is the optimal location for bone conduction, posterior auricular PPG, and unobtrusive presence. Other surfaces, wrist, finger, eyewear, are inferior for every Orí use case. Focus is the strategy. The platform extends through software, longitudinal data, and clinical partnerships, not through additional form factors.

Market Context

The category is not theoretical.
It is being defined right now.

40-50M

Sweetpea unit target, year one

$6.5B

OpenAI's acquisition of io

H2 2026

Sweetpea launch window

1

Architectural alternative, Orí

From the founder

"Orí is not a better AI assistant. It is the first system in history designed to make technology disappear so the human using it can finally appear."

Carlos E. Marciano · Founder · 2% Technologies LLC

Reach the founder→